Atara Biotherapeutics y Pierre Fabre Laboratories publica los datos de fase 3 ALLELE Tab-cel®
Atara Biotherapeutics y Pierre Fabre Laboratories anuncian la publicación de los datos de fase 3 ALLELE Tab-cel® en The Lancet Oncology
Se publican los primeros resultados de la fase 3 de una terapia alogénica de células T
Related news for (ATRA)
- Atlanta Braves Holdings to Host Its First Investor Day
- Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
- Atlanta Braves Holdings Announces Fourth Quarter and Year End 2024 Earnings Release and Quarterly Conference Call
- Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219